Lineage Cell Therapeutics Inc

NYSE American: LCTX    
Share price (5/3/24): $1.05    
Market cap (5/3/24): $198 million
Search in Documents
Key Exhibits
External Links

Indentures Filter

EX-4.3
from S-3 53 pages Lineage Cell Therapeutics, Inc., Issuer and [Trustee], Trustee Indenture Dated as of [●], 20__ Debt Securities
12/34/56
EX-4.7
from S-3 19 pages Lineage Cell Therapeutics, Inc. and , as Warrant Agent Form of Debt Securities Warrant Agreement Dated as of Lineage Cell Therapeutics, Inc. Form of Debt Securities Warrant Agreement
12/34/56
EX-4.6
from S-3 21 pages Lineage Cell Therapeutics, Inc. and , as Warrant Agent Form of Preferred Share Warrant Agreement Dated as of Lineage Cell Therapeutics, Inc. Form of Preferred Share Warrant Agreement
12/34/56
EX-4.5
from S-3 22 pages Lineage Cell Therapeutics, Inc. and , as Warrant Agent Form of Common Share Warrant Agreement Dated as of Lineage Cell Therapeutics, Inc. Form of Common Share Warrant Agreement
12/34/56
EX-4.2
from 10-K 2 pages Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934
12/34/56
EX-4.3
from S-3 53 pages Lineage Cell Therapeutics, Inc., Issuer and [Trustee], Trustee Indenture Dated as of [●], 20__ Debt Securities
12/34/56
EX-4.7
from S-3 19 pages Lineage Cell Therapeutics, Inc. and , as Warrant Agent Form of Debt Securities Warrant Agreement Dated as of Lineage Cell Therapeutics, Inc. Form of Debt Securities Warrant Agreement
12/34/56
EX-4.6
from S-3 21 pages Lineage Cell Therapeutics, Inc. and , as Warrant Agent Form of Preferred Share Warrant Agreement Dated as of Lineage Cell Therapeutics, Inc. Form of Preferred Share Warrant Agreement
12/34/56
EX-4.5
from S-3 22 pages Lineage Cell Therapeutics, Inc. and , as Warrant Agent Form of Common Share Warrant Agreement Dated as of Lineage Cell Therapeutics, Inc. Form of Common Share Warrant Agreement
12/34/56
EX-4.3
from S-3 53 pages Lineage Cell Therapeutics, Inc., Issuer and [Trustee], Trustee Indenture Dated as of [●], 20__ Debt Securities
12/34/56
EX-4.2
from 10-K 2 pages Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934
12/34/56
EX-4.2
from S-8 2 pages 2017 Amendment to Biotime, Inc. 2012 Equity Incentive Plan
12/34/56
EX-4.4
from S-3 45 pages Biotime, Inc. Issuer and as Trustee Indenture Dated as of , 20 Debt Securities
12/34/56
EX-4.1
from 8-K 14 pages Oncocyte Corporation Common Stock Warrant
12/34/56
EX-4.1
from S-8 26 pages Biotime, Inc. 2012 Equity Incentive Plan as Amended
12/34/56
EX-4.1
from 8-K 19 pages Warrant Agreement Dated as of October 1, 2013 as Amended September 19, 2014
12/34/56
EX-4.1
from 8-K 2 pages Indenture or similar
12/34/56
EX-4.3
from POS AM 2 pages Purchase Form
12/34/56
EX-4.1
from 8-K 18 pages Warrant Agreement Dated as of October 1, 2013
12/34/56
EX-4.1
from 8-K 20 pages [Form of Warrant Certificate] Biotime, Inc. Warrants to Purchase Common Stock
12/34/56